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Background:Mood disorder is common in cervical dystonia and can impact on quality of
life. It often precedes the onset of cervical dystonia and does not improve with botulinum
toxin therapy.
Objective: To assess health-related quality of life in relation to mood disorder and
measures of severity, disability and pain, in cervical dystonia patients receiving botulinum
toxin therapy.
Methods: In a single-center, University Hospital movement disorders clinic, we
conducted a comprehensive, cross-sectional study of disease severity, non-motor
symptoms, mood and health-related quality of life in patients with cervical dystonia
receiving botulinum toxin therapy using TWSTRS-2 for pain, severity and disability; Beck
Anxiety Inventory and Beck Depression Inventory. We assessed all variables in relation
to health-related quality of life assessed by Cervical Dystonia Impact Profile-58 and the
Euro-QoL Utility Index.
Results: In 201 patients (136 women), mean age 61.5 years, significant determinants
of impaired health related quality of life were: being a woman, reporting a history
of anxiety or depression, prevalent pain, disability, anxiety and/or depression but not
physician-assessed disease severity.
Conclusion: Patient-reported measures of pain, disability and, most markedly, mood
disorder, are significant factors affecting quality of life; these were totally unrelated to
the neurologist-rated measure of disease severity. Mood disorders, the predominant
predictor of quality of life, were not addressed in the botulinum toxin clinic.
Keywords: cervical dystonia, non-motor symptoms, anxiety, depression, mood disorder, health-related quality
of life
INTRODUCTION
Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions
causing abnormal, often repetitive, movements, postures, or both (1).
Adult-onset idiopathic focal dystonia (AOIFD) is the most common form of dystonia; the most
common phenotype is cervical dystonia (2). Although considered primarily a motor disorder, non-
motor symptoms, especially mood disorders, with resulting impaired health related quality of life
(HrQoL), are commonly observed in cervical dystonia (3–18). Mood disorders may precede the
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onset of the motor symptoms of dystonia (8), and do not improve
with botulinum toxin therapy (3, 5); they are considered a
primary feature of AOIFD, not secondary.
In cervical dystonia, disease impact is commonly measured
by the validated Toronto Western Spasmodic Torticollis Rating
Scales (TWSTRS-2) scales of Disability, Severity and Pain (19).
The TWSTRS-2 Severity scale is physician-rated; the Disability
and Pain scales are patient-reported. The TWSTRS-2 Total is
used commonly as summary measure and has been shown to be
responsive to change in botulinum toxin trials.
The Cervical Dystonia Impact Profile-58 (CDIP-58) is
a commonly-used, multi-dimensional, disease-specific, patient
self-report of HrQoL (20, 21). The inter-relationships between
physician-assessedmotor severity and patient-reported measures
of disease impact and HrQoL have been seldom assessed.
We aimed, in our cervical dystonia clinic population, to
examine the inter-relationships between motor and non-motor
symptom severity, using these validated instruments in relation
to measures of mood disorder and HrQoL measured by both the
CDIP-58 and a generic instrument.
MATERIALS AND METHODS
Study Participants
The study participants had been diagnosed with adult-onset
isolated idiopathic cervical dystonia (CD) according to standard
diagnostic criteria by two experienced neurologists; they were
attending our single-center Movement Disorders clinic for
botulinum toxin therapy. We excluded patients with: (a) other
forms of dystonia at onset (generalized, segmental, other focal
dystonias), (b) other neurological disorders and comorbidities
(cognitive impairment) that would confound assessment or
preclude completion of questionnaires. All patients were assessed
just prior to their next scheduled botulinum injection, usually
3 months after the last injection. Patients were recruited
consecutively at the clinic; given the relatively large group,
patients were recruited from July 2018 to January 2020 (roughly
over 18 months).
Methods
We collected basic demographic information, including current
age, age at onset of cervical dystonia, duration of cervical
dystonia, the presence of a history, and time of onset,
of a medically diagnosed anxiety or depression (given by
any medical practitioner), social history, and other medical
background history.
Measures
Pain, severity and disability were assessed using the revised
TorontoWestern Spasmodic Torticollis Rating Scales (TWSTRS-
2); TWSTRS-2 Severity assessed by three experienced, trained,
raters (IN, SO’R, and MH); TWSTRS-2 Pain and Disability
reported by the participants; TWSTRS-2 Total was calculated
(19). For current anxiety and depression assessment, we used
the Beck Anxiety Inventory (BAI) and the Beck Depression
Inventory-II (BDI-II) (22–25). For HrQoL measures, we used
the disease-specific measure, Cervical Dystonia Impact Profile-
58 (CDIP-58) (20, 21) and a generic assessment tool, Euro-Qol-
Utility Index (EQoL-UV) (26). For all assessment tools, except
the Euro-Qol-UV (Utility Index), higher scores indicate worse
symptoms/impact; with the Euro-Qol-UV, the closer the number
is to 1, the better the quality of life.
Statistical Analysis
Power Analysis
The total population of cervical dystonia in Ireland determined in
a previous epidemiological study from the group, was estimated
as 410 patients (27). A sample size calculator, using 95%
confidence level and a 5% confidence interval, indicates we
should have at least 196 patients in our sample size (28). Thus,
we consider that our sample size (201 patients) in relation to
population size is adequately powered.
Statistical Analytical Methods
Means with standard deviation, medians and interquartile range
(IQR) were used to describe the distribution of our dataset. We
used the Mann-Whitney (M-W) test to compare the differences
between two independent groups with dependent variables, given
the non-Gaussian distribution of our data as evidenced by the
Anderson-Darling, D’Agostin and Pearson, Shapiro-Wilk, and
Kilmogorov-Smirnov tests. Significance level was defined as p <
0.05; there was no correction for multiple significance testing.
The inter-relationship between variables was assessed by simple
linear andmultiple variable regression using Prism 8 (GraphPad).
Separate analyses were performed: (1): in the total cohort, (2): by
sex and (3): by a history of anxiety and/or depression prior to




Two hundred and thirteen patients fulfilled the study criteria;
12 (6%) patients did not complete all assessments and thus 201
were included in the analysis; there were 136 women (68%) and
65 men (32%). Their mean (±SD) current age was 61.5 (±12.7)
years; mean age at onset of CD was 43.6 (±12.8) years and mean
duration of CD was 17.9 (±11.9) years (Table 1).
Sex Differences
There were no significant differences betweenmen and women in
age, duration of CD or years of formal education (Table 1). Men
had an earlier median age at onset of CD than women (women:
45 years, men: 39 years; MWU = 3,369; p = 0.0062). TWSTRS-2
Total scores were marginally significantly worse for women than
men [TWSTRS-2 Total (median, IQR) scores for women = 31
(20, 43); for men = 26 (21, 34); MWU = 3,639; p = 0.043)];
there were no significant sex differences in the TWSTRS-2 Pain,
Disability and Severity scale scores (Table 1).
Women reported worse Health-Related Quality of Life
(HrQoL) than men both by the Utility Index (p = 0.037) and
by the CDIP−58 (p = 0.0088) (Table 1). All CDIP-58 subscale
measures were larger (worse/more impact) in women than men
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TABLE 1 | Characteristics of cervical dystonia cohort by sex and history of mood disorder.
Groups (N) All (201) Women (136) Men (65) History of mood disorder (79) No h/o mood disorder (122)
CURRENT AGE (Y)
Mean (SD) 61.5 (12.7) 62.9 (12.2) 58.5 (13.3) 59.7 (12.4) 62.6 (12.8)
Median (range) 62 (31–90) 63 (33–90) 60 (31–86) 62 (33–90) 63 (31–90)
(ns) (ns)
AGE AT CD ONSET (Y)
Mean (SD) 43.6 (12.84) 45.5 (12.8) 39.7 (12.1) 41.2 (12.0) 45.1 (13.2)
Median (range) 44 (20–79) 45 (20–79) 39 (20–65) 41 (20–66) 45 (20–79)
(p = 0.006) (p = 0.039)
DURATION OF CD (Y)
Mean (SD) 17.9 (11.97) 17.4 (12.1) 18.8 (11.7) 18.5 (13.1) 17.5 (11.3)
Median (range) 16 (0.16-60) 15 (0.16–60) 17 (2–49) 18 (0.16–60) 16 (1.5–59)
(ns) (ns)
TWSTRS-2 TOTAL
Mean (SD) 30.4 (14.4) 32 (15) 27 (12) 33.6 (15) 28.7 (13.9)
Median (IQR) 30 (19, 40) 31 (20,43) 26 (21,34) 34 (21, 46) 29 (19, 37.3)
(p = 0.043) (p = 0.03)
TWSTRS-2 PAIN
Mean (SD) 13.6 (9.7) 14 (10) 12 (8.7) 14.9 (9.8) 12.8 (9.5)
Median (IQR) 14 (5, 20) 15 (5.3, 22) 13 (5.0, 18) 15 (8, 22) 14 (4, 19)
(p = 0.111) (p = 0.15)
TWSTRS-2 SEVERITY
Mean (SD) 10.4 (4.6) 11 (4.5) 9.8 (5.0) 10.8 (4.8) 10.1 (4.5)
Median (IQR) 11 (7, 13) 11 (8, 13) 10 (6, 12) 10 (7, 14) 11 (7, 13)
(p = 0.16) (p = 0.65)
TWSTRS-2 DISABILITY
Mean (SD) 6.5 (4.9) 6.9 (4.9) 5.8 (5.1) 7.7 (5.1) 5.8 (4.8)
Median (IQR) 6 (2, 10) 6.0 (3, 9.5) 5.0 (2, 9.5) 7 (4, 11) 5 (2, 9)
(p = 0.114) (p = 0.0067)
BECK ANXIETY INVENTORY
Mean (SD) 11 (11) 12 (11) 9.6 (11) 16.8 (13.1) 7.1 (7.1)
Median (IQR) 7 (3, 16) 8 (4, 17) 6.0 (2, 14) 13 (8, 26) 5 (2, 9.3)
(p = 0.07) (p< 0.0001)
BECK DEPRESSION INVENTORY
Mean (SD) 11.6 (10.4) 12 (10) 10 (10) 17 (11.6) 7.9 (7.6)
Median (IQR) 9.0 (3, 18) 11 (4, 19) 7.0 (3, 16) 16 (8, 24) 6 (2, 12)
(p = 0.09) (p< 0.0001)
UTILITY INDEX
Mean 0.712 0.6873 0.7628 0.620 0.771
(SD) 0.259 (0.2708) (0.2265) (0.287) (0.221)
Median 0.789 0.755 0.820 0.681 0.827
IQR 0.611, 0.902 0.586, 0.871 0.661, 0.932 0.435, 0.852 0.676, 0.932
(p = 0.037) (p< 0.0001)
CDIP-58
Mean (SD) 32.4 (21.9) 35 (23) 26 (18) 38.5 (22.2) 28.6 (22.2)
Median (IQR) 31 (14, 47) 35 (17, 49) 23 (12, 38) 37 (21, 51) 24 (11.8, 44)
(p = 0.0088) (p = 0.002)
Study population characteristics: Demographic characteristics, disease impact and Quality of Life in all (a): 201 cervical dystonia patients, divided (b): by sex (136 women and 65 men)
and (c): by a reported history of mood disorder (79 with and 122 without). Measures of dystonia impact by TWSTRS-2 Total, Pain, Severity, Disability, with measures of anxiety (Beck
Anxiety Inventory), depression (Beck Depression Inventory) and quality of life (by the Utility Index and CDIP-58). Significant group differences are in bold. Women reported significantly
worse TWSTRS-2 Total scores and worse quality of life. Patients with a history of mood disorder, at any time, had ongoing more severe TWSTRS-2 Total and Disability, ongoing more
severe depression, anxiety and worse quality of life (TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; CDIP-58, Cervical Dystonia Impact Profile−58).
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TABLE 2 | Cervical Dystonia Impact Profile-58: Total scores and Subscale scores in 201 patients with cervical dystonia subdivided by sex and history of a mood disorder.
Groups (N) ALL (201) WOMEN (136) MEN (65) History of mood disorder (79) No h/o mood disorder (122)
CDIP-58 TOTAL
Mean (SD) 32.5 (21.9) 35 (23) 26 (18) 38.5 (22.2) 28.6 (20.8)
Median (IQR) 31 (15, 47) 35 (17, 49) 23 (12, 38) 37 (21, 51) 24 (11.8, 44)
(p = 0.0088) (p = 0.002)
HEAD AND NECK
Mean (SD) 52.6 (27) 55 (29) 48 (23) 57.8 (25.0) 49.2 (27.7)
Median (IQR) 54 (33,75) 57 (33, 78) 52 (33, 63) 58 (42, 75) 50 (25,75)
(p = 0.118) (p = 0.042)
PAIN
Mean (SD) 44.9 (30.7) 47 (32) 40 (27) 51.2 (29.6) 40.9 (30.3)
Median (IQR) 45 (17.5,75) 48 (20, 75) 35 (15,63) 55 (25,75) 35(15,70)
(p = 0.103) (p = 0.0188)
UPPER LIMB
Mean (SD) 31.4 (25.6) 36 (26) 22 (22) 35.9 (25.9) 28.4 (25)
Median (IQR) 28 (7, 51.5) 33 (14, 56) 17 (0, 41) 33 (14, 56) 23.5 (5, 48)
(p=0.0002) (p = 0.038)
WALKING
Mean (SD) 25.4 (26.3) 29 (28) 18 (21) 28.6 (27.9) 23.3 (25.2)
Median (IQR) 17 (0, 47) 21 (1, 50) 14 (0, 30) 17 (0, 50) 17 (0, 39)
(p = 0.0127) (p = 0.234)
SLEEP
Mean (SD) 26.7 (29.2) 30 (30) 20 (26) 34 (30.3) 22 (27.6)
Median (IQR) 19 (0, 50) 19 (0, 50) 6 (0, 35) 31 (0, 56) 6 (0, 38)
(p = 0.037) (p = 0.0028)
ANNOYANCE
Mean (SD) 28.5 (26.7) 31 (28) 23 (22) 36.2 (28.4) 23.4 (24.4)
Median (IQR) 19 (6, 50) 22 (6, 50) 16 (3, 43) 34 (13, 53) 16 (3, 38)
(p = 0.073) (p = 0.0014)
MOOD
Mean (SD) 23.9 (27.1) 26 (28) 19 (24) 35.2 (30.7) 16.6 (21.7)
Median (IQR) 11 (0, 39) 18 (4, 39) 7 (0, 38) 25 (7, 57) 7 (0, 29)
(p = 0.065) (p< 0.0001)
PSYCHOSOCIAL
Mean (SD) 34.7 (29.0) 37 (30) 30 (26) 40.8 (30.4) 30.7 (27.4)
Median (IQR) 28 (10, 54) 28 (13, 60) 23 (10, 45) 33 (18, 68) 24 (10, 50)
(p = 0.177) (p = 0.0138)
Cervical Dystonia Impact Profile−58 (CDIP-58): CDIP-58 Total and subscale scores [means, standard deviations (SD) medians and interquartile range (IQR)] in the study population of
201 patients. Comparison of CDIP-58 scores for 136 women and 65 men and also scores for the 79 patients with a history of a diagnosis of a mood disorder compared to 122 patients
with no history of mood disorder. Women report significantly worse CDIP-58 Total, “Sleep,” “Upper Limb” and “Walking” subscale scores than men. A history of diagnosed mood
disorder is associated with more disease impact in all measures except the “Walking” subscale. Group medians were compared by non-parametric, Mann Whitney testing; significant
inter-group comparisons are illustrated in bold.
but only significantly worse for the subscales “Sleep” (p <
0.038), “Upper limb symptoms” (p = 0.0002) and “Walking”
(p= 0.012) (Table 2).
History of Mood Disorder
46/201 (23%) patients had a history of a medical diagnosis
of anxiety or depression prior to cervical dystonia onset;
[35/136 women (26%) and 11/65 men (17%); NS]. These
patients had persisting anxiety and/or depression; at review,
their BAI and BDI-II scores remained markedly significantly
worse than patients with no history of prior mood disorder,
even after 15–20 years of dystonia (p = 0.0097 and p = 0.0008,
respectively; Figure 1).
A history of a medically diagnosed mood disorder at any
stage was reported by 79/201 (39%) (MD group); [58/136
women (42.6%) and 21/65 men (32.3%); NS]. In these 79
patients, compared to the 122 without such a history, the age
of onset of cervical dystonia was 4 years earlier (p = 0.039)
(Table 1). TWSTRS-2 Total scores were significantly worse in
the 79 patients with a history of mood disorder (p = 0.03);
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FIGURE 1 | The prolonged effects of preceding mood disorder in cervical
dystonia. Evidence of significant persisting anxiety and depression measured
by the Beck Anxiety inventory (BAI) and Beck Depression Inventory (BDI-II)
scores, ∼18 years after disease onset, in 46 cervical dystonia patients (blue
circles) with preceding anxiety/depression compared to 155 with none (pink
circles) (bars indicate medians ± inter-quartile intervals).
this difference was driven by a markedly worse patient self-
report of TWSTRS-2 Disability in these patients (p = 0.0067).
As one might have anticipated, the 79 patients with a history
of mood disorder reported significantly worse BAI and BDI-II
scores (both p < 0.0001) (Table 1).
Current Mood Disorder Prevalence
Taking a very conservative measure of prevalent significant
anxiety or depression, using the BAI (scores> 15) and the BDI-II
(scores > 13), 37 /136 (27%) women had current anxiety, 49/136
(36%) had current depression, 53/136 (39%) had either anxiety or
depression and 33/136 (24%) had both. For the 65 men 15 (23%)
had current anxiety, 18 (28%) had current depression, 22 (34%)
had either anxiety or depression and 11 (17%) had both.
Determinants of Disease Impact by HrQoL
Measures
Using CDIP-58 as the HrQoL Standard
Whole group analysis (Table 3 and Figure 2)
Within the whole group of 201 patients, using the CDIP-58 as
the reference HrQoL measure, there were moderate correlations
of the CDIP-58 with the BAI (r2 = 0.388), the BDI-II (r2 =
0.319), the TWSTRS−2 Total (r2 = 0.386) and the patient
reported TWSTRS-2 Pain (r2 =0.268) andDisability (r2 = 0.289)
subscales. The correlation of the CDIP-58 with the, physician-
assessed, TWSTRS-2 Severity score was extremely low at r2 =
0.09. The BAI (p < 0.0001), the TWSTRS-2 Total (p < 0.0001),
and subscales Pain (p < 0.0001) and Disability (p < 0.0001)
survived multivariable analysis (Table 3).
Women
For the 136 women, the CDIP-58, as the dependent variable,
correlatedmost strongly with the TWSTRS−2 Total (r2 = 0.421),
the BAI (r2 = 0.361), BDI-II (r2 = 0.302), the patient-reported
TWSTRS−2 Pain (r2 = 0.29) and TWSTRS−2 Disability
scales (r2 = 0.28); the correlation with the, physician assessed,
TWSTRS−2 Severity score was low at r2 = 0.11. The BAI (p =
0.0014), the TWSTRS−2 Total (p < 0.0001), Pain (p < 0.0001),
and the TWSTRS−2 Disability subscales (p < 0.0001) survived
multivariable analysis (Figure 2).
Men
For the 65 men, by single regression analysis, the most significant
determinants of HrQoL, measured by the CDIP−58, were the
BAI (r2 = 0.47) and BDI-II (r2 = 0.36); the TWSTRS-2 Total
(r2 = 0.31) and subscale Disability correlations were similar,
the physician assessed, TWSTRS-2 Severity subscale correlation
was extremely small. Only the BAI (p = 0.0006) and TWSTRS-
2 Total (p = 0.0015) survived multivariable analysis (Table 3
and Figure 2).
Utility Index as the HrQoL Standard
Whole group analysis (Table 3)
For the 201 patients, the Utility Index, used as the reference
HrQoL dependent variable, correlated most strongly with the
BAI (r2 = 0.367), the BDI (r2 = 0.321), TWSTRS-2 Total
(r2 = 0.186) and the patient-reported TWSTRS-2 Disability scale
(r2 = 0.20). The correlation of Utility Index with the, physician-
assessed, TWSTRS-2 Severity score was extremely low at r2 =
0.039. The BAI (p < 0.0001), BDI (p = 0.017) the TWSTRS-2
Total (p = 0.001) and TWSTRS−2 Disability scale (p = 0.001)
survived multivariable analysis (Table 3).
Women
For the 136 women, the Utility Index as the dependent variable,
correlated most highly with the BAI (r2 = 0.319) and the BDI-
II (r2 = 0.31); the correlation with the TWSTRS−2 Total was
much weaker at r2 = 0.145; most of this correlation related to
the TWSTRS−2–Disability subscale (r2 = 0.158); the physician
assessed TWSTRS−2 Severity correlation was extremely weak
at r2 = 0.04 (Table 3). The BAI (p = 0.007), the BDI-II (p
= 0.02) and the TWSTRS−2 Disability subscale (p = 0.007)
survived multivariable analysis (Figure 3); The TWSTRS-2 Total
also survived (p = 0.047) when assessed separately from the
subscales (and clearly was driven by Disability subscale).
Men
For the 65 men, the highest correlations of the Utility Index
were with the BAI (r2 = 0.498), the BDI-II (r2 = 0.349) and
the TWSTRS−2 Total (r2 = 0.34). Correlations within the
TWSTRS−2 subscales were: Disability (r2 = 0.31) and Pain (r2 =
0.24); the, physician-assessed, Severity correlation was r2 = 0.03
(Table 3). The BAI (p = 0.0003), TWSTRS−2 Total (p = 0.004),
Pain (p = 0.003) and Disability subscales (p = 0.03) survived
multivariable analysis (Figure 3).
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TABLE 3 | Determinants of Health-related Quality of Life in 201 patients with cervical dystonia.
Dependent variable TWSTRS-2 Pain TWSTRS-2 Disability TWSTRS-2 Severity TWSTRS-2 Total BAI BDI-II
R-squared relationship with the dependent variable
ALL 201 PTS
CDIP-58 0.268**** 0.289**** 0.09 0.386**** 0.388**** 0.319
Utility Index 0.110 0.200*** 0.039 0.186*** 0.367**** 0.321*
136 WOMEN
CDIP-58 0.291**** 0.282**** 0.116 0.421**** 0.361** 0.302
Utility Index 0.070 0.158** 0.04 0.145* 0.319** 0.306*
65 MEN
CDIP-58 0.17 0.30 0.056 0.307** 0.47*** 0.36
Utility Index 0.238** 0.305* 0.020 0.34** 0.498*** 0.349
Disease characteristic measures which are determinants of Health-related Quality of Life in 201 patients with cervical dystonia. Health-related Quality of Life (HrQoL) assessed by the
Cervical Dystonia Impact Profile−58 (CDIP-58) and the EuroQoL Utility Index. Correlations (r-squared) between these HrQoL measures with patient reported levels of TWSTRS-2 Pain,
TWSTRS-2 Disability, the physician-assessed TWSTRS-2 Severity; also, the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory (BDI-II). Significant correlations, surviving
multiple variable analysis, are in bold (* < 0.05; ** <0.01; *** < 0.001; **** <0.0001) (TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale).
FIGURE 2 | Correlations with the Cervical Dystonia Impact Profile-58
(CDIP-58) as an index of Quality of Life. Correlations of CDIP-58 with other
measures of disease impact in 136 women (pink bars) and 65 men (blue bars)
with cervical dystonia. The height of the bars indicates the r-squared
relationship between the CDIP-58 Total Scale score and the clinical measure.
In women there were significant correlations, surviving multi-variable analysis,
between the CDIP-58 with TWSTRS-2 Total, Pain, Disability and Beck Anxiety
Inventory (BAI). In men, only the TWSTRS Total and BAI correlations survived
multi-variable analysis. [BAI, Beck Anxiety Inventory; BDI-II, Beck Depression
Inventory; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale) (*p
< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)].
DISCUSSION
In this study, we found that HrQoL in cervical dystonia, assessed
by both a generic measure (EuroQoL Utility Index) and a disease
specific instrument, the CDIP-58, is overwhelmingly determined
by a combination of factors: anxiety, depression and the patient’s
report of pain and disability (TWSTRS-2 Pain and TWSTRS-2
Disability). Non-motor symptoms, in particular mood disorder,
were the predominant determinants of the patient’s HrQoL, as
FIGURE 3 | Correlations with the Utility Index as a measure of Quality of Life.
Simple linear regression (r-squared) associations of the Utility Index with other
measures of disease impact in 136 women (pink bars) and 65 men (blue bars)
with cervical dystonia. The height of the bars indicates the univariate r-squared
relationship between the Utility Index and the clinical measure. In 136 women,
the TWSTRS-2 Total, TWSTRS-2 Disability subscale, Beck Anxiety Inventory,
and Beck Depression Inventory (BDI-II) correlations survived multi-variable
analysis. In 65 men there were significant separate correlations, surviving
multi-variable analysis, between the Utility Index and the TWSTRS-2 Total,
TWSTRS-2 Pain, and Disability subscales and with the Beck Anxiety Inventory
(BAI). [TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; BAI,
Beck Anxiety Inventory; BDI-II, Beck Depression Inventory; (*p < 0.05; **p <
0.01; ***p < 0.001.
has been indicated by others (discussed below). Factors which did
not show correlation with HrQoL in our study included, duration
of cervical dystonia, years of formal education, and current age.
The size of the variances of measures of mood, particularly
anxiety, indicates that at least 40–50% of HrQoL impairment
may be attributable to a psychological disorder intrinsic to
cervical dystonia which is not currently addressed in the
clinic. One of the problems of a busy botulinum toxin clinic,
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with repeated 3-monthly injections, is that the patient-doctor
interaction is directed purely at the mechanical injection process
and not with the unspoken, and not enquired about, considerable
psychological morbidity.
One noteworthy aspect of this study is that disease severity,
assessed by the neurologist using the TWSTRS-2 Severity scale,
on univariate analysis, had a negligible contribution to HrQoL
in comparison to the patient-reported measures TWSTRS-2
Pain and TWSTRS-2 Disability. Both the latter were the most
significant contributors to the TWSTRS−2 Total score and
most relevant to HrQoL, either measured by the Utility Index
or the CDIP-58. The TWSTRS Severity scale has been noted
to be insensitive to change; in an assessment of minimally
important clinical change in the TWSTRS score (CD PROBE)
it was reported that the Severity subscale was least useful of
all the three subscales (29); a comprehensive review of rating
scales indicates the difficulties in measuring cervical dystonia
severity, not all which can be overcome by ensuring good inter-
rater reliability (30). A recent multidimensional assessment of
HrQoL and psychiatric morbidity in cervical dystonia also found
no effect of TWSTRS-2 Severity assessment (12). It could be
argued we should discontinue using physician assessment of
disease severity by the TWSTRS-2 methodology, especially in
CD patients already established on long-term botulinum toxin
therapy; we should pay more attention to patient report from
measures such as the TWSTRS-2 Disability, Pain and the CDIP-
58. It is possible that the future technological development of
wearable devices to assess the severity of motor symptoms over
the period of several days prior to the clinic visit, might be a useful
objective measure of the severity of motor symptoms; at present
it would appear that the summary expert neurologist’s assessment
of disease severity at the clinic visit is less than useful.
Our Findings in the Context of Previous
Research
There have been, over the last 10 years, a number of
comprehensive reviews of non-motor symptoms (including
psychiatric symptoms) in adult onset focal dystonia (3, 7, 31).
There have also been a number of studies using relatively few
participants (14) and with a mixture of various phenotypes
of focal dystonia, which makes comparison to the present
study difficult.
The Epidemiological Study of Dystonia in Europe
Collaborative Group was one of the first to assess HrQoL,
using the SF-36, in a number of participants with cervical
dystonia; in a postal survey of 286 European patients with
cervical dystonia, men reported better HrQoL scores than
women, which were significantly different in relation to pain and
“physical function” (32). When compared to other neurological
conditions including stroke, multiple sclerosis and Parkinson’s
disease, patients with cervical dystonia scored worst in relation
to HrQoL. Using the same database, and with measures of mood,
a further paper noted that, following multivariable analysis,
the strongest predictors of HrQoL in this population were
depression and anxiety, although self-reported severity remained
a significant variable; it was noted that longer disease duration
was a significant ameliorating factor in reported HrQoL (4).
A Polish study of 101 patients with cervical dystonia on
treatment with botulinum toxin noted that depression (found
in 47% of patients) was the main predictor of poorer HrQoL;
women reported poorer quality of life (33). Surprisingly, not
in keeping with our findings, they noted that longer treatment
duration was associated with a beneficial effect; given that this
study was carried out in the first few years after the introduction
of botulinum toxin, this beneficial effect might be attributable to
a comparison with the physical state prior to its introduction.
A Norwegian study in 2007 assessed 70 patients with cervical
dystonia using TWSTRS, HADS-D and a quality of life measure,
the SF-36; they found that mean SF 36 scores in the patients
were reduced by one standard deviation compared to the general
population; the main factors associated with reduced scores in
the physical and mental domains of the SF 36 was the TWSTRS
Total and the HADS-D scores, respectively (13). Surprisingly,
compared to other reports they found that patients with a good
response to botulinum toxin had both lower TWSTRS scores
and less depression. A German study in 2009, in 86 patients
(predominantly cervical dystonia) noted an increased risk of
various psychiatric disorders including depression with an odds
ratio of 3.0 and 21.6 for social phobia (10). A postal survey study
in 2009 from Sweden of 279 cervical dystonia patients using the
CDIP-58 reported similar but slightly higher, scores in all of the
subscales than we found; there was no concurrent measure of
mood disorder or generic quality of life to compare with our
patient sample (16).
There was a very influential case-control Italian study of
89 patients with various forms of focal dystonia (34 had
cervical dystonia) from Fabbrini et al. (8). They used 62 healthy
control participants; 64% of the cervical dystonia patients had a
psychiatric disorder compared to 25% of healthy controls; this
was due to an increased rate of major depression; the prevalence
of anxiety was not increased; in 15/22 (68%) cervical dystonia
patients with a psychiatric disorder the psychiatric disorder had
begun prior to the movement disorder (8). A follow-up to that
paper noted that, when reassessed 5 years later, the patients had
not improved from the point of view of the psychiatric symptoms,
although the severity of their dystonia was milder at the second
assessment (5). The authors concluded that the psychiatric
symptoms were independent of the motor symptomatology.
An important Dutch case-control study intensively assessed
psychiatric morbidity in 50 patients with cervical dystonia, the
cervical dystonia population had a 64% prevalence of psychiatric
disorders compared to 28% in a control population; depression
prevalence was 32% vs. 14%; anxiety 42% vs. 8%; other psychiatric
disorders were not increased in frequency (12). They also found,
similar to our results, that, following multivariable analysis,
HrQoL was strongly predicted by high scores on the BDI-
II, BAI, TWSTRS-2 Disability and TWSTRS-2 Pain. TWSTRS-
2 Disability was significantly associated with the severity of
depression measured by the BDI-II (r2 = 0.28); TWSTRS-2
Pain was significantly associated with TWSTRS-2 Disability and
with anxiety measured by the BAI (r2 = 0.32). Smit et al. also
noted, similar to our findings, that dystonia motor severity (by
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TWSTRS-2 Severity) had no influence on disability, pain or
HrQoL (12).
A recent, very comprehensive, report from the Dystonia
Coalition noted that 32.8% of their 255 cervical dystonia patients
(from multiple centers) had depression by the BDI-II (>13)
and 43.8% had anxiety by the HADS-A (>7); they noted that
their data confirmed the large and growing body of evidence
of the coexistence of depression and anxiety with isolated focal
dystonia (6).
In our study, we found a high prevalence of anxiety and/or
depression based on a medically diagnosed history (almost 40%),
and on using assessment tools (about 40%); this supports the
accumulating evidence of the high prevalence of anxiety and
depression in dystonia patients (12–14, 17, 18). While depression
(by BDI-II and a known history) is more prevalent than anxiety
(by BAI and a known history) in our study, anxiety (by BAI)
showed more impact on quality of life than depression (by
BDI-II); this has not been described before.
The strengths of our study include the homogeneity of the
dystonia phenotype and size of our single-center, cohort, together
with the 96% response rate in participation. One limitation of our
study is the inevitable retrospective reporting by our patients of
the presence, and time of onset, of mood disorder relative to the
onset of their cervical dystonia, although this would have been
recorded in their medical notes at their initial consultation.
CONCLUSIONS
Patient-reported measures, particularly the CDIP-58, are more
sensitive and reflective of health-related quality of life than
the physician-administered standard recommended measure of
cervical dystonia severity in patients receiving botulinum toxin
therapy. The ability to control motor symptoms of cervical
dystonia using botulinum toxin therapy has major benefits.
However, recognizing and addressing anxiety and depression in
these patients is necessary to improve their quality of life. There
is an increasing consensus that psychiatric symptoms, anxiety
and depression, are a primary symptom of adult onset dystonia
(not secondary to the movement disorder). It is considered
that these psychiatric symptoms indicate disordered processing
within limbic–striatal systems and are due to the same underlying
processes, which cause the movement disorder.
The logical imperative is that movement disorders
neurologists must address these psychiatric symptoms and
resulting disability; although a recent short duration randomized
control study of escitalopram was negative (34), longer duration,
randomized-controlled trials of SSRI therapy in cervical dystonia
are warranted.
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